🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Waldenstrom Macroglobulinaemia

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Exercise, Diet Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia NCT04061512Phase 2, Phase 325 sites📍 Bath📍 Bournemouth📍 Canterbury University College, London · Tests: Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2150 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process NCT07160270n/a1 site📍 København Ø Copenhagen University Hospital, Rigshospitalet Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas NCT04883437Phase 21 site📍 Atlanta Emory University · Tests: Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019Phase 136 sites📍 Gilbert📍 Newark📍 Pompano Beach Schrödinger, Inc. · Tests: SGR-1505 A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia NCT06986174Phase 21 site📍 Boston Shayna Sarosiek, MD · Tests: Pacritinib Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427n/a1 site📍 Taipei National Taiwan University Hospital · Tests: ctDNA analyzed by phased variant A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) NCT07231952Phase 29 sites📍 Boston📍 Boston📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Pirtobrutinib, Venetoclax, Rituximab Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762Phase 11 site📍 San Francisco C. Babis Andreadis · Tests: Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies NCT04195633Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893Phase 2121 sites📍 Springdale📍 La Jolla📍 Torrance Merck Sharp & Dohme LLC · Tests: Nemtabrutinib SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies NCT06708897Phase 15 sites📍 Louisville📍 Chapel Hill📍 Cincinnati Lomond Therapeutics Holdings, Inc. · Tests: Lonitoclax (ZE50-0134)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy